Skip to main navigation

Careers    |    Contact    |    News    |   

  • About Arbutus
    • Overview
    • Management
    • Our Board
    • Scientific Advisory Board
    • Careers
  • About HBV
    • HBV Background
    • HBV Science
    • The Baruch S. Blumberg Institute
  • >
  • R&D Portfolio
    • HBV Assets
      • AB-729 (GalNAc-RNAi)
      • AB-836 (Oral Capsid Inhibitor)
      • AB-101 (Oral PD-L1 Inhibitor)
      • AB-161 (Oral HBV RNA Destabilizers)
    • Coronavirus
  • Partners
    • Partnering & Licensing
    • Collaborations & Partners
  • Investors
    • Investor Center
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Investor FAQ
    • Contact Us

Investor Relations

  • Investor Center
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Press Releases
  • Events & Presentations
  • Investor FAQ
  • Contact Us

Press Releases

  • Summary ToggleTekmira Comments on Market Activity
    Jul 09, 2007
    Tekmira Comments on Market Activity 14.6 KB

    ...

    Read more
  • Summary ToggleTekmira Pharmaceuticals Provides Operational Update at AGM
    Jun 20, 2007
    Tekmira Pharmaceuticals Provides Operational Update at AGM 20.3 KB

    ...

    Read more
  • Summary ToggleTekmira Pharmaceuticals Releases First Quarter 2007 Operating Results
    May 15, 2007

    ...

    Read more
  • Summary ToggleTekmira Pharmaceuticals Conference Call Advisory 2007 First Quarter Operating Results
    May 10, 2007
    Tekmira Pharmaceuticals Conference Call Advisory 2007 First Quarter Operating Results 12 KB

    ...

    Read more

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 43
  • Page 44
  • Page 45
  • Current page 46
Displaying 451 - 454 of 454 results

Shareholder Tools

  • Email Alerts Email Alerts
  • RSS News Feeds RSS News Feeds
  • Download Library Download Library

© 2022 Arbutus Biopharma

Legal Terms